Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in...read more
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and a few SPACs scheduled to raise at least $900 million. Russian e-commerce company Ozon Holdings (OZON) plans to raise $750 million at a $4.4...read more
Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed. The diverse group had very mixed trading, and averaged a return of 9.9%. New...read more
Atea Pharmaceuticals, a Phase 2 biotech developing therapies for COVID-19 and other viral diseases, raised $300 million by offering 12.5 million shares at $24, the high end of the range of $22 to $24 according to an S-1MEF filed with the SEC. The company...read more
Biotech IPOs close to beating Covid-19
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in...read more
US IPO Week Ahead: The IPO market takes a break during the shortened holiday week
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and a few SPACs scheduled to raise at least $900 million. Russian e-commerce company Ozon Holdings (OZON) plans to raise $750 million at a $4.4...read more
US IPO Weekly Recap: Big fintechs fall as 11 IPOs squeeze in ahead of the election
Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed. The diverse group had very mixed trading, and averaged a return of 9.9%. New...read more
COVID-19 viral biotech Atea Pharmaceuticals prices upsized IPO at $24 high end
Atea Pharmaceuticals, a Phase 2 biotech developing therapies for COVID-19 and other viral diseases, raised $300 million by offering 12.5 million shares at $24, the high end of the range of $22 to $24 according to an S-1MEF filed with the SEC. The company...read more